Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

The Quick Take
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Update zur Geschäftsentwicklung in den ersten neun Monaten 2026
Strategische Fortschritte erzielen und Wachstumsaussichten stärken ATHEN, Griechenland und LONDON, 6. November 2026 /PRNewswire/ -- METLEN Energy & Metals PLC…
Local
Firefighters rescue cat from burning home in south Las Vegas valley - KSNV
Firefighters rescue cat from burning home in south Las Vegas valley KSNV
Business
Chewy chief accounting officer sells $110,745 in stock
Business
